Natera

Natera previously filed infringement lawsuits against ArcherDx around four other patents related to cell-free DNA detection in oncology.

Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.

Results from the Phase II INSPIRE study showed that change in ctDNA from baseline, as gauged by customized assays, predicted response to pembrolizumab.

Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.

News items for the in vitro diagnostics industry for the week of June 22, 2020.

The suit comes shortly after Progenity filed for an initial public offering in which it is seeking to raise up to $122.6 million.

News items for the in vitro diagnostics industry for the week of June 1, 2020.

In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."

The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.

Noridian is also developing a generic policy for donor-derived cfDNA tests that will include several commercially available tests, Natera said.